Annual Meeting ProceedingsAmerican Society of Clinical Oncology, 2004 |
From inside the book
Results 1-3 of 77
Page 275
... toxicity & early mortality ( Rothenberg , JCO 2001 ) , Intergroup N9741 concurrently randomized 355 of a planned 600 patients ( pts ) with CRC to FOLFOX - 4 or R - IFL . Randomization was terminated early due to superior results on ...
... toxicity & early mortality ( Rothenberg , JCO 2001 ) , Intergroup N9741 concurrently randomized 355 of a planned 600 patients ( pts ) with CRC to FOLFOX - 4 or R - IFL . Randomization was terminated early due to superior results on ...
Page 469
... toxicity of PLD administered at a lower dose ( 40 mg / m2 ) is not well - characterized . Methods : Medical charts of all patients who initiated PLD at a starting dose of 40 mg / m2 from 1997-2003 for the treatment of gynecologic ...
... toxicity of PLD administered at a lower dose ( 40 mg / m2 ) is not well - characterized . Methods : Medical charts of all patients who initiated PLD at a starting dose of 40 mg / m2 from 1997-2003 for the treatment of gynecologic ...
Page 630
... toxicity . The final analysis , however , showed that the overall toxicity for PS2 pts was similar to that for PS 0-1 patients . The overall response rate for PS 2 patients was 14 % , median survival was 4.1 months and 1 year survival ...
... toxicity . The final analysis , however , showed that the overall toxicity for PS2 pts was similar to that for PS 0-1 patients . The overall response rate for PS 2 patients was 14 % , median survival was 4.1 months and 1 year survival ...
Contents
data is that preoperative breast biopsy does not cause artificial tumour cell | 22 |
Side Irradiated | 33 |
A novel tumor marker of potential utility in metastatic | 46 |
Copyright | |
20 other sections not shown
Other editions - View all
Common terms and phrases
activity administered adverse events analysis anthracycline antibody antitumor apoptosis assessed Background baseline biopsy breast cancer breast cancer patients Cancer Center Cancer Institute capecitabine carboplatin carcinoma clinical trial cohort colorectal cancer combination Conclusions correlated cycles diarrhea docetaxel dose level doxorubicin drug effects efficacy EGFR enrolled erlotinib evaluated follow-up G-CSF gefitinib gemcitabine gene Germany grade HER2 Hospital Imatinib infusion inhibition inhibitor irinotecan liver median age metastatic metastatic breast cancer Methods mg/m² months neoadjuvant neutropenia observed Oncology oral overall survival oxaliplatin paclitaxel patients pts patients received patients with advanced pharmacokinetic phase II study phase II trial plasma Poster Discussion Poster Session primary prior progression protein pts received radiotherapy randomized range receptor recurrence regimen respectively response rate Results rituximab significant solid tumors stable disease surgery tamoxifen taxane therapy tolerated toxicity trastuzumab treated treatment tumor tumor cells University vaccine VEGF vinorelbine weeks women